Pure oestrogen antagonists for the treatment of advanced breast cancer

Anthony Howell

CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK

Abstract

For more than 30 years, tamoxifen has been the drug of choice in treating patients with oestrogen receptor (ER)-positive breast tumours. However, research has endeavoured to develop agents that match and improve the clinical efficacy of tamoxifen, but lack its partial agonist effects. The first ‘pure’ oestrogen antagonist was developed in 1987; from this, an even more potent derivative was developed for clinical use, known as fulvestrant (ICI 182,780, ‘Faslodex’). Mechanistic studies have shown that fulvestrant possesses high ER-binding affinity and has multiple effects on ER signalling: it blocks dimerisation and nuclear localisation of the ER, reduces cellular levels of ER and blocks ER-mediated gene transcription. Unlike anti-oestrogens chemically related to tamoxifen, fulvestrant also helps circumvent resistance to tamoxifen. There are extensive data to support the lack of partial agonist effects of fulvestrant and, importantly, its lack of cross-resistance with tamoxifen. In phase III studies in patients with locally advanced or metastatic breast cancer, fulvestrant was at least as effective as anastrozole in patients with tamoxifen-resistant tumours, was effective in the first-line setting and was also well tolerated. These data are supported by experience from the compassionate use of fulvestrant in more heavily pretreated patients. Further studies are now underway to determine the best strategy for sequencing oestrogen endocrine therapies and to optimise dosing regimens of fulvestrant. At present, and for the foreseeable future, fulvestrant is the only oestrogen antagonist with no agonistic effects licensed for the treatment of advanced breast cancer in postmenopausal women. Other similar oestrogen antagonists are undergoing research and development, with a few currently being evaluated in phase II trials.
used in tamoxifen-resistant disease have led to their development being halted. Toremifene (chloro-tamoxifen), which has similar efficacy but fewer agonist properties compared with tamoxifen (Marttunen et al. 1998, 2001), remains in clinical development in the breast cancer prevention setting.

Structurally distinct second- and third-generation SERMs (‘fixed-ring’ benzo thiophene derivatives (Fig. 1)) such as raloxifene, arzoxifene and ERA-923 were then developed. Most of these have demonstrated anti-tumour activity in breast cancer but also have some partial agonist activity (Buzdar et al. 1988, Gradishar et al. 2000, Munster et al. 2001, Buzdar et al. 2003). Results from the Study of Tamoxifen and Raloxifene (STAR) trial, one of the largest breast cancer prevention studies, which has recruited 19 000 postmenopausal women at risk of breast cancer, are expected in 2006. Based on its partial oestrogen agonist effects (Delmas et al. 1997), raloxifene is also currently being used for the prevention and treatment of osteoporosis and breast cancer. Arzoxifene showed promising initial results in a phase II study in advanced breast cancer, although its efficacy was greater in tamoxifen-sensitive than tamoxifen-resistant disease (Buzdar et al. 2003). Results from a phase I study suggest that ERA-923 has no trophic effects on the uterus (Cotreau et al. 2002), and its role in patients with breast cancer is currently being investigated.

The search for novel agents that would completely block all ER signalling led to the synthesis of a series of steroidal 7α-alkylamide analogues of oestradiol. Of these, ICI 164,384 was the first pure oestrogen antagonist to be described, completely blocking the uterotrophic action of both oestradiol and tamoxifen in rats (Wakeling & Bowler 1987). Following this, a far more potent pure oestrogen antagonist was developed, ICI 182,780, which is now known as fulvestrant (‘Faslodex’) (Fig. 1) (Wakeling et al. 1991). At present (and for the foreseeable future), fulvestrant, an oestrogen antagonist with no agonist effects, is licensed for the treatment of advanced breast cancer in postmenopausal women. Therefore, this paper will describe in detail the mode of action of fulvestrant, and explore how this underlies its clinical efficacy, tolerability and safety profile in the treatment of advanced breast cancer. In considering the future directions for oestrogen-antagonistic agents, ongoing clinical trials with fulvestrant will be reviewed. The current status of other ‘pure’ oestrogen antagonists in preclinical and clinical development will also be described.

### Mode of action

#### ER-mediated signalling

The biological actions of oestrogen are mediated by two subtypes of ER, ERα and ERβ. Both receptors belong to a family of ligand-activated nuclear transcription factors (Evans 1988) and share a high degree of homology in their DNA binding domains.
(Kuiper et al. 1996). However, they differ considerably in their N-terminal regions, which contain the ligand-independent transcription activation function, AF1 (Kuiper et al. 1996). These differences suggest that ERα and ERβ could have distinct functions in terms of gene regulation and may contribute to the selective action of oestradiol in different target tissues (Gustafsson & Warner 2000). There is evidence from in vitro studies to suggest that imbalanced ERα/ERβ expression may be a feature of oestrogen-dependent tumour progression and that ERβ has a key role in providing protection against ERα-induced hyperproliferation (Bardin et al. 2004). It has also been suggested that ERβ may be a dominant regulator of oestrogen signalling as it causes a dose-dependent reduction in ERα-mediated transcription when coexpressed with ERα (Lindberg et al. 2003).

Classical pathway of ER signalling

In classical ER signalling, unbound ER can be nuclear localised and bound loosely to the oestrogen response elements (ERE) (Kumar & Chambon 1988, Reese & Katzenellenbogen 1991). However, binding of oestradiol to the ER initiates a cascade of events leading to strong ER dimerisation, increased nuclear localisation and binding to ERE in the regulatory regions of target genes, and gene transcription (mediated by AF1 and AF2 of the ER) (Beato 1989, Tsai & O’Malley 1994, Ch eskis et al. 1997). AF1 (located in domains A and B of the amino terminal of the ER) is activated by growth factors acting through the mitogen-activated protein kinase (MAPK) pathway, while AF2 (located in domain E of the carboxy terminal of the ER ligand-binding domain) is activated by oestradiol. In the transcription complex, the activated AFs recruit coactivators and corepressors of oestrogen-regulated transcription (Horwitz et al. 1996, White & Parker 1998), with full transcriptional activity requiring both AFs to be active. Ligand-specific conformational changes in the ER strongly influence the protein:protein interactions in the transcriptional complex, leading to differences in gene transcription and activation for ER-binding ligands (Brzozowski et al. 1997, Shiau et al. 1998). Indeed, ligand-dependent conformational changes in the ER show that there are distinct differences between oestradiol–ER, tamoxifen–ER and fulvestrant–ER complexes (Paige et al. 1999).

Nonclassical pathways of ER signalling

In addition to binding to classical ERE motifs, ERs can stimulate gene transcription via a nonclassical pathway by interacting with other transcription factors bound to promoters of responsive genes. Genes that are regulated by oestrogen but do not have an ERE include cyclin D1, p21 and the PgR (Shupnik 2004). Many such genes are regulated via ER interactions with stimulating protein 1 (Sp1), the signal transducers and activators of transcription (STAT) family of transcription factors and transcription factors associated with activating protein 1 (AP1) sites. The AP1 transcription factors are a family of homo- and heterodimers composed of proteins that belong to the Jun, Fos, Maf and ATF subfamilies that bind to 12-0-tetradecanoylphorbol-13-acetate (TPA) response elements (TRE) or cAMP response elements (CRE) in target genes (Chinenov & Kerppola 2001). The c-Jun homodimer is the most potent transcriptional activator in the AP1 family (Matthews et al. 2006).

While both ERα and ERβ can bind oestradiol and activate transcription through an ERE, they have differential transcriptional activities at Sp1 and AP1 sites. Only ERα can stimulate genes via the Sp1 pathway and the two isoforms are differentially regulated by oestrogens and antioestrogens at AP1 sites (Shupnik 2004). Results of a recent in vitro study suggested that ERβ may preferentially antagonise the nonclassical AP1-mediated pathway regulated by ERα (Matthews et al. 2006). Interestingly, another in vitro study suggests that ER expression may positively contribute to breast cancer growth in two ways. In normal situations, ER is activated by oestrogen to promote breast cancer cell proliferation, primarily through ERE-mediated transcription. However, in stressful conditions, such as during chemotherapy treatment, ER may facilitate breast cancer growth by inhibiting cell death via binding c-Jun and regulating AP1-mediated transcription (Qi et al. 2004).

Ligand-independent ER signalling pathways

During recent years, it has been documented that crosstalk between oestrogen and growth factor-stimulated intracellular signalling pathways can directly activate the ER and the transcription of ER-regulated genes in the absence of oestrogen (Weigel & Zhang 1998). As AF1 is activated via factors involved in the MAPK pathway, crosstalk exists between the ER, growth factor receptors (e.g. human epidermal growth factor receptors 1 and 2 (EGFR and HER2)) and kinase pathways (Nicholson & Johnston 2005). ER–growth factor receptor cross-talk is thought to be involved in the development of resistance to endocrine therapy by reducing the reliance on oestrogen-sensitive proliferation. As such, inhibition of growth factor receptor pathways, particularly in conjunction with inhibition
of ER signalling, may provide additional ways of circumventing endocrine resistance (Nicholson & Johnston 2005).

‘Non-genomic’ actions of oestradiol

In addition to the classical action of ER as a ligand-regulated transcription factor, oestradiol also exerts early signalling events within target cells minutes after stimulation, making it likely that these effects are independent of transcription. These processes may be mediated by membrane-associated ER (Hanstein et al. 2004) or the G-coupled membrane receptor GPR30 (Filardo & Thomas 2005). Activation of membrane-associated ER has been shown to lead to activation of MAPK signalling, phosphatidylinositol-3-kinase (PI-3K) signalling and a rise in cytoplasmic calcium levels. It can also activate release of epithelial growth factor (EGF) and insulin-like growth factor (IGF), thus leading to stimulation of EGFR and IGFR, respectively (Hanstein et al. 2004). GPR30 can act independently of ERα and ERβ and has been linked to oestrogen-mediated regulation of the EGFR to MAPK signalling axis via stimulation of adenylyl cyclase activity (Filardo et al. 2000, 2002, Filardo & Thomas 2005).

Effect of partial oestrogen antagonists upon oestrogen signalling

Even though the affinity of tamoxifen for the ER is 2.5% that of oestradiol (Wakeling & Bowler 1987, Wakeling et al. 1991), tamoxifen has similar molecular effects to oestradiol once bound to the ER (Katzenellenbogen et al. 1996) (i.e. increased nuclear translocation and ERE binding of the tamoxifen–ER complex). This may be due to the fact that the major mediator of tamoxifen action is 4-hydroxy-tamoxifen, which has been shown to have a similar affinity for the ER as oestradiol (Borgna & Rochefort 1980). Tamoxifen, idoxifene and raloxifene have all been shown to increase ERz protein and mRNA levels in MCF-7 cells (Wijayaratne et al. 1999), possibly as a result of their oestrogen agonist activity.

The gene-specific actions of partial oestrogen antagonists such as tamoxifen, toremifene and raloxifene (all of which are non-steroidal in structure) can be accounted for by several factors, including ligand affinity and differences in ER conformation, and differences in the efficiency of coactivators and corepressors coupling to the transcriptional complex Katzenellenbogen et al. 1996). While AF2 is inactivated in the tamoxifen–ER complex, AF1-mediated transcription is unaffected by tamoxifen. The partial agonism observed with tamoxifen is attributed to AF1 activity, which itself is dependent upon cellular and promoter factors (Berry et al. 1990, Tzukerman et al. 1994). Other SERMs such as idoxifene and raloxifene also inhibit ER AF2 but show partial agonist activity against AF1 in MCF-7 cells (Wijayaratne et al. 1999). However, not all of the biological effects of partial oestrogen antagonists may be explained by their ability to differentially regulate AF1 and AF2, as other AF domains may also exist that only function when AF1 and AF2 are inactive. Indeed, an autonomous activation domain, referred to as AF2a, has already been described (Norris et al. 1997), although the impact of partial oestrogen antagonists on this domain remains unclear. Thus, the effects of these agents are likely to be cell, promoter and effector sensitive, which may explain their differential actions on bone, the cardiovascular system and the uterus.

Although ERz and ERβ AF1 generally exhibit weak activity at genes with classical EREs, there are certain cellular environments in which differential effects of SERMs on AF1 activity at EREs are detectable. In such situations, tamoxifen-bound ERz has similar activity to unbound AF1 and raloxifene-bound ERz has less activity. When bound by the pure antioestrogen, ICI 164,384, ERz has no activity at all. These differences appear to be due to differential recruitment of corepressors (Webb et al. 2003). Other oestrogen agonist effects of SERMs stem from ER activity at genes with alternate response elements. For example, ERz enhances AP1 activity in the presence of tamoxifen and shows weaker activity in the presence of raloxifene (Paech et al. 1997). SERMs can also enhance AP1 activity via an AF-independent mechanism; here, raloxifene strongly enhances ERz action whereas tamoxifen does not (Webb et al. 2003). Therefore, SERMs differentially regulate two mechanisms of ER action at AP1 sites.

Effect of pure oestrogen antagonists upon oestrogen signalling

Fulvestrant is a 7α-alkylsulphinyl analogue of 17β-oestradiol that is structurally distinct from the non-steroidal oestrogen antagonists. The C7 side chain of fulvestrant is crucial for its mode of action; it differentiates fulvestrant from oestradiol, and its position, length and flexibility determine the pure antagonistic activity of fulvestrant (Bowler et al. 1989). This chemical structure is also responsible for the important differences between fulvestrant and tamoxifen. First, the binding affinity of fulvestrant to the ER is 89% that of oestradiol (Wakeling & Bowler 1987). Secondly, the conformational change induced by
fulvestrant binding means that ER homodimerisation and energy-dependent nuclear-cytoplasmic shuttling is prevented, blocking nuclear localisation of the ER (Fawell et al. 1990, Dauvois et al. 1993). In addition, cellular levels of ER are decreased via several mechanisms: turnover is increased, half-life is decreased and there is rapid ER degradation (Fawell et al. 1990, Dauvois et al. 1992, Wijayaratne et al. 1999).

Fulvestrant also disables both AF1 and AF2 on ERα; thus, even if any fulvestrant–ER complexes are present in the nucleus, gene transcription is abrogated, despite the fact that the fulvestrant–ER complex binds DNA (Wijayaratne et al. 1999). As mentioned previously, when ERα is bound to the pure antioestrogen, ICI 164,384, no AF1 activity is detectable at classical EREs (Webb et al. 2003). Fulvestrant has been shown to inhibit ERα-mediated transcription from an ERE in MCF-7 cells more effectively than tamoxifen, raloxifene or idoxifene (Wijayaratne et al. 1999). In contrast to tamoxifen, pure antioestrogens can strongly enhance ERα activity at API sites via an AF-independent mechanism (Webb et al. 2003). A recent cDNA microarray study has also highlighted the differences in levels of ER antagonism between fulvestrant and the SERMs (Frasor et al. 2004). Here, fulvestrant was shown to antagonise the expression of 95% of oestrogen-upregulated genes and 91% of oestrogen-downregulated genes. In contrast, tamoxifen antagonised expression of only 47% of oestrogen-upregulated genes and 26% of oestrogen-downregulated genes. The antagonistic activity of raloxifene was somewhere in between, being 67% for oestrogen-upregulated and 33% for oestrogen-downregulated genes. Conversely, only tamoxifen had full agonistic activity on a substantial proportion of genes; 23% of those upregulated by oestrogen and 31% of those downregulated. In contrast, fulvestrant and raloxifene had full agonistic activity on ≤8% of oestrogen-regulated genes overall (Frasor et al. 2004).

Fulvestrant has also been shown to affect rapid, ‘nongenomic’ oestrogen signalling via membrane-associated ER. Activation of the MAPK pathway via oestrogen stimulation of membrane-associated ER is abolished by fulvestrant in vitro; however, activation of MAPK via EGF is unaffected (Improt Brears et al. 1999). Interestingly, as seen with oestrogen, both fulvestrant and tamoxifen have been shown to activate GPR30-mediated stimulation of adenylyl cyclase, leading to cAMP-mediated inhibition of Erk-1 and Erk-2 and the attenuation of the EGFR-MAPK signalling cascade (Filardo et al. 2000, 2002).

Fulvestrant may help to circumvent hormone resistance via pathways of receptor cross-talk by reducing cellular ER levels (Hutcheson et al. 2003). Indeed, one major difference between fulvestrant and tamoxifen is the ability of fulvestrant to abrogate ER activation mediated by other signalling factors, such as EGFR, IGFR and dopamine (Ignar-Trowbridge et al. 1993, Smith et al. 1993, Newton et al. 1994). In contrast, tamoxifen is unable to block the activation of ER by the same mediators (Ignar-Trowbridge et al. 1993, Smith et al. 1993, Newton et al. 1994).

**Biological effects of pure oestrogen antagonists**

There is extensive preclinical data to support the pure oestrogen antagonist effects of fulvestrant. In vitro, fulvestrant significantly decreased ER protein levels and inhibited PgR expression in MCF-7 cells (McClelland et al. 1996). In contrast, tamoxifen increased MCF-7 ER (oestrogen withdrawal has a similar effect) and PgR protein levels (Horowitz & McGuire 1978, Nicholson et al. 1995, Early Breast Cancer Trialists’ Collaborative Group 1998, Hutcheson et al. 2003). In vivo, a single 5 mg dose of fulvestrant (short-acting formulation) was as effective as tamoxifen (10 mg/kg/day orally) in blocking the growth of MCF-7 xenografts in nude mice (Wakeling et al. 1991). In addition, fulvestrant (5 mg weekly) suppressed the growth of established MCF-7 xenografts in mice for twice as long as tamoxifen (500 μg/day) or oestrogen withdrawal, and was more effective than tamoxifen in reducing the expression of oestrogen-regulated genes in MCF-7 xenograft tissue (Osborne et al. 1995).

The effect of short-term administration of fulvestrant on breast cancer was initially evaluated in 56 women with primary breast cancer who were randomised to receive no preoperative treatment (n = 16) or daily i.m. fulvestrant (n = 37 (6 mg, n = 21; 18 mg, n = 16)) for 7 days prior to primary breast surgery (DeFriend et al. 1994). There was no evidence of agonist activity using fulvestrant, which significantly reduced tumour ER (median ER index, 0.72 before vs 0.02 after treatment; \( P < 0.001 \)), PgR (median PgR index, 0.50 before vs 0.01 after treatment; \( P < 0.05 \)) and Ki67 (median Ki67 labelling index, 3.2 before vs 1.1 after treatment; \( P < 0.05 \)) expression levels (DeFriend et al. 1994). More recently in the preoperative setting, 201 postmenopausal women with stage T1-3 breast cancer were treated with fulvestrant (50 mg, 125 mg or 250 mg on day 0 as an i.m. injection), tamoxifen (20 mg/day orally) or tamoxifen placebo for 14–21 days prior to surgery of curative intent (Robertson et al. 2001). Tumour biopsies (taken at...
baseline and during surgery 15–22 days after dosing) were analysed for ER and PgR levels (H-score), proliferation (Ki67 levels) and apoptosis markers. ER levels were significantly decreased by tamoxifen when compared with placebo ($P = 0.049$) and by all doses of fulvestrant compared with placebo ($P < 0.026$) (Fig. 2). In addition, ER levels were significantly decreased by 250 mg fulvestrant compared with tamoxifen ($P = 0.024$). While tamoxifen significantly increased PgR levels compared with placebo ($P = 0.009$), fulvestrant, 125 mg and 250 mg, significantly reduced PgR levels compared with either placebo or tamoxifen ($P \leq 0.003$). Although, fulvestrant and tamoxifen significantly reduced proliferation compared with placebo ($P < 0.046$ for both), none of the treatment arms affected apoptotic indices (Robertson et al. 2001). The differential effects on PgR levels observed highlight the ‘pure’ oestrogen antagonist effects of fulvestrant. A more recent study has analysed the effect of long-term pre- and postoperative fulvestrant (250 mg/month) on ER expression in patients with locally advanced or metastatic breast cancer (Robertson et al. 2004). Nineteen out of 24 patients experienced clinical benefit (CB), and this group had a significant reduction in tumour ER levels after 4–6 weeks and 6 months of treatment compared with pretreatment levels ($P = 0.029$ and $P = 0.011$ respectively). In contrast, ER levels were not significantly reduced in the five patients with progressive disease (PD) at the 4–6 weeks time point (Robertson et al. 2004). Thus, fulvestrant can maintain ER suppression for a sustained period (beyond 6 months), and downregulation may be higher in those experiencing CB than those with de novo progression. The presence of tumour ER in all patients at the time of progression supports the use of further endocrine therapy after fulvestrant.

Moreover, ER expression in patients with PD might provide insights into mechanisms of resistance through growth factor receptor cross-talk. The amount of cross-resistance observed between tamoxifen and the newer partial antagonists being developed was a major problem. Importantly, cross-resistance between fulvestrant and tamoxifen has not been observed in vitro; fulvestrant is a far more potent inhibitor of tamoxifen-sensitive and tamoxifen-resistant MCF-7 proliferation (~150 and 1540 times more potent than tamoxifen respectively) (Hu et al. 1993), and tamoxifen inhibits both fulvestrant-sensitive and fulvestrant-resistant MCF-7 cell lines (Lykkesfeldt et al. 1995). In vivo, the growth of tamoxifen-resistant MCF-7 xenografts in nude mice (generated following treatment with 500 μg/day tamoxifen for 6 months) was abrogated by fulvestrant (5 mg/week) (Osborne et al. 1994). These data suggested that fulvestrant had potential in the treatment of patients with tamoxifen-resistant tumours.

**Lack of agonist effects**

Despite the fact that tamoxifen is well tolerated, the risks of thromboembolic disease and endometrial

---

**Figure 2** Percentage change in tumour oestrogen receptor (ER) and progesterone receptor (PgR) levels using short-term fulvestrant in patients with ER-positive and PgR-positive tumours. Biopsies were taken prior to treatment and during surgical excision 15–22 days later. Based on data in Robertson et al. (2001).
cancer increase with long-term use due to partial agonist activity (Fisher et al. 1994, 1996, Early Breast Cancer Trialists’ Collaborative Group 1998). In contrast, a wealth of preclinical and clinical data show that the pure oestrogen antagonist fulvestrant lacks these partial agonist effects.

In vivo, fulvestrant (0.03–1.0 mg/kg/day for 14 days) inhibited the uterotrophic effect of oestradiol (0.5 μg) or tamoxifen (1 mg/kg) in immature or ovariectomised rodents in a dose-dependent manner (Wakeling et al. 1991). In contrast, tamoxifen only partially blocked the uterotrophic activity of oestradiol (Wakeling et al. 1991). Fulvestrant (4 mg short-acting formulation) also inhibited oestradiol-induced increases in endometrial volume in ovariectomised primates to below that present at the start of the menstrual cycle (Dukes et al. 1993). Moreover, the rate and extent of endometrial involution were similar to that observed following oestradiol withdrawal, demonstrating a lack of oestrogen-agonist effects (Dukes et al. 1993). In both of these animal models, fulvestrant was not associated with the uterine hyperplasia often observed with tamoxifen treatment.

These preclinical data have been supported by data from a study in healthy volunteers. In a phase I trial, 30 healthy postmenopausal women received a single dose i.m. 125 mg or 250 mg fulvestrant or placebo, followed 2 weeks later by 20 μg/day ethinyloestradiol for 2 weeks (Addo et al. 2002). No evidence of agonist activity in the endometrium was observed. Moreover, 250 mg fulvestrant abrogated the mean change in oestrogen-stimulated endometrial thickening after 21 days of treatment (1.5 mm vs. 8.1 mm; P < 0.001) (Addo et al. 2002). Thus, fulvestrant lacks oestrogen agonist activity on the normal human postmenopausal endometrium.

**Clinical efficacy of pure oestrogen antagonists**

**In tamoxifen-resistant advanced breast cancer**

Preclinical data suggesting that fulvestrant may be beneficial in the treatment of tamoxifen-resistant tumours (Hu et al. 1993, Osborne et al. 1994) have been supported by the efficacy of fulvestrant in patients with this type of breast cancer. In a small, initial clinical study (n = 19), over two-thirds (69%) of postmenopausal women with tamoxifen-resistant disease treated with fulvestrant experienced CB (Howell et al. 1996). Moreover, a long duration of response (DoR) was observed in these women (median duration 25 months) (Howell & Robertson 1995, Howell et al. 1996), supporting preclinical evidence that fulvestrant suppressed tumour growth for longer than tamoxifen (Osborne et al. 1995). Thus, fulvestrant was shown not to be cross-resistant with tamoxifen in the clinical setting.

These data were confirmed more recently in two phase III trials in postmenopausal women with advanced breast cancer who previously had progressed after receiving anti-oestrogen treatment (Howell et al. 2002, Osborne et al. 2002). Both studies had a similar design, in which fulvestrant (250 mg/month i.m., n = 428) was compared with the aromatase inhibitor (AI) anastrozole (1 mg/day orally, n = 423). In one study, fulvestrant was administered as a single 5 ml injection in an open-label comparison (International), whereas in the other study fulvestrant was administered as two separate 2.5 ml injections in a double-blind comparison (North American). The results of a prospectively designed, combined analysis of these studies are presented here.

Most patients in the fulvestrant and anastrozole groups had progressed following previous treatment with tamoxifen (96 vs 97% respectively), and both groups were generally well matched at baseline for age, weight, prior therapy, hormone receptor status and extent of metastatic or recurrent disease (Robertson et al. 2003). At median follow-up of 15.1 months, the median time to progression (TTP) (Fig. 3) was comparable in both groups (5.5 vs 4.1 months for fulvestrant and anastrozole respectively; hazard ratio (HR) 0.95; 95.14% confidence interval (CI) 0.82, 1.10; P = 0.48). The objective response (OR; complete response (CR) + partial response (PR)) rate was not significantly different between the two groups, being 19.2% in the fulvestrant group compared with 16.5% in
the anastrozole group \((P=0.31)\). In addition, there were no differences in OR rates between fulvestrant and anastrozole in the subgroup of patients who had any visceral metastases \((15.7 \text{ vs } 13.2\% \text{ respectively}; \ P=0.49)\) or those with visceral metastases only \((18.8 \text{ vs } 14.0\% \text{ respectively}; \ P=0.43)\) (Mauriac et al. 2003). Furthermore, fulvestrant demonstrated similar efficacy in patients with/without visceral metastases.

In patients who had an OR, further follow-up was performed at a median of 22.1 months (Robertson et al. 2003). The median DoR was 16.7 and 13.7 months in those patients who responded to fulvestrant \((n=84)\) and anastrozole \((n=73)\) respectively (Fig. 4); mean duration of response was significantly greater for fulvestrant than anastrozole \((\text{HR } 1.30; \ 95\% \text{ CI } 1.13, 1.50; \ P<0.01)\) (Robertson et al. 2003). A similar proportion of patients experienced CB \((\text{OR}+\text{ stable disease (SD)})\) for \(\geq 24\) weeks; 43.5\% patients receiving fulvestrant and 40.9\% patients receiving anastrozole) and the median duration of CB was also similar between the groups \((11.8 \text{ vs } 11.2\text{ months respectively).}\)

A survival analysis conducted at a median follow-up of 27.0 months showed that the overall survival was very similar with fulvestrant and anastrozole \((\text{median } 27.4 \text{ vs } 27.7\text{ months respectively}; \text{ HR } 0.98; \ 95\% \text{ CI } 0.84, 1.15; \ P=0.809)\), and that three-quarters of the patients had died in each group \((74.5 \text{ vs } 76.1\% \text{ respectively})\) (Howell et al. 2005). Indeed, as the upper 95\% CI was below the predefined limit of 1.25, fulvestrant may be considered non-inferior to anastrozole in terms of overall survival benefit.


### As first-line therapy for advanced breast cancer

The efficacy of first-line fulvestrant vs tamoxifen has been investigated in postmenopausal women with metastatic or locally advanced breast cancer. In a phase III study, endocrine-naı̈ve patients or patients who had completed endocrine therapy \(\geq 1\) year previously were treated with either fulvestrant \((250 \text{ mg/month i.m. injection with placebo tamoxifen}, \ n=313)\) or tamoxifen \((20 \text{ mg/day orally with placebo fulvestrant}, \ n=274)\) (Howell et al. 2004). Approximately 20–25\% of patients had received prior adjuvant tamoxifen therapy for their primary breast cancer.

After a median follow-up of 14.5 months, there was no significant difference between fulvestrant and tamoxifen for the primary endpoint TTP \((\text{median } 6.8 \text{ vs } 8.3\text{ months respectively}; \text{ HR } 1.18; \ 95\% \text{ CI } 0.98, 1.44; \ P=0.088; \text{ Table 1})\). OR rates were similar between the two arms \((31.6\% \text{ for fulvestrant vs } 33.9\% \text{ for tamoxifen});\) however, CB rates were significantly higher in the tamoxifen group \((54.3\% \text{ for fulvestrant vs } 62.0\% \text{ for tamoxifen}; \ P=0.026)\). In patients experiencing an OR, the median DoR was similar \((17.3 \text{ vs } 19.8\text{ months with fulvestrant and tamoxifen respectively})\) (Howell et al. 2004). Thus, in the overall (intent-to-treat \((\text{ITT})\)) population between-group differences in efficacy favoured tamoxifen and the statistical non-inferiority of fulvestrant could not be demonstrated.

**Table 1** Impact of hormone receptor status on time to progression with fulvestrant vs tamoxifen in patients with advanced breast cancer (Howell A, Robertson JFR, Abram P, Lichinister MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I et al. 2004 Comparison of fulvestrant vs tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multi national, double blind, randomized trial. Journal of Clinical Oncology 22 1605–1613. Reprinted with permission from the American Society of Clinical Oncology.)

<table>
<thead>
<tr>
<th>Patient population</th>
<th>(n) (%)</th>
<th>HR</th>
<th>95% CI</th>
<th>(P)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant</td>
<td>313 (100)</td>
<td>1.18</td>
<td>0.98, 1.44</td>
<td>0.088</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>274 (100)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER+ and/or PgR+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant</td>
<td>247 (78.9)</td>
<td>1.10</td>
<td>0.89, 1.36</td>
<td>0.39</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>212 (77.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER+ and PR+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fulvestrant</td>
<td>131 (41.9)</td>
<td>0.85</td>
<td>0.63, 1.15*</td>
<td>0.31</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>114 (41.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HR, hazard ratio; CI, confidence interval; ITT, intent-to-treat; ER+, oestrogen receptor positive; PgR+, progesterone receptor positive.

*Non-inferiority of fulvestrant to tamoxifen is shown by an upper 95\% CI of \(\leq 1.25\).
The ITT population contained >20% of patients for whom the ER status was negative or unknown. Given the modes of action of tamoxifen and fulvestrant, patients with hormone receptor-positive breast tumours may be expected to gain the greatest benefit from these drugs. In a prospectively planned analysis of those patients with ER-positive and/or PgR-positive breast tumours (>75% of patients), median TTP was similar between fulvestrant and tamoxifen (8.2 vs 8.3 months respectively; HR 1.10; 95% CI 0.89, 1.36; \( P = 0.39 \); Table 1, Fig. 5) (Howell et al. 2004). Furthermore, similar rates for CB (57.1 vs 62.7%; HR 0.79; 95% CI −15.01, 3.19; \( P = 0.22 \)) and OR (33.2 vs 31.1%; HR 1.10; 95% CI 0.74, 1.63; \( P = 0.64 \)) were observed in the fulvestrant and tamoxifen groups respectively. Therefore, in patients with hormone receptor-positive tumours, fulvestrant and tamoxifen had similar efficacy.

In an additional post-hoc analysis of patients with breast tumours that were positive for both ER and PgR (~42% of patients), the findings for median TTP were again shown to be comparable in the two groups (11.4 vs 8.5 months for fulvestrant and tamoxifen respectively; HR 0.85; 95% CI 0.63, 1.15; \( P = 0.31 \); Table 1) (Buzdar 2004). Further studies of first-line fulvestrant are warranted, specifically in patients with confirmed hormone receptor-positive breast tumours, as these patients represent the intended treatment population for the drug.

Experience from a compassionate-use programme

Treatment options are severely limited in postmenopausal women with advanced breast cancer who have received multiple prior therapies (endocrine or chemotherapy). For patients who were not eligible to receive fulvestrant as part of a clinical trial and in countries where fulvestrant was not yet approved, fulvestrant was available as part of a compassionate-use programme (Franco et al. 2004, Petruzelka et al. 2004, Steger et al. 2005).

In the largest report from a single centre, data are available from 126 patients (80% had received fulvestrant as second- or third-line endocrine therapy and 60% had received palliative chemotherapy). Of these women, 12 (9.5%) had a PR and 43 (34%) had SD ≥6 months with fulvestrant treatment resulting in a CB rate of 44% (Steger et al. 2005). Notably, 43/108 patients (40%) who had received prior non-steroidal AI treatment gained CB with fulvestrant. Breast tumours were ER-positive and PgR-positive in 9/12 patients experiencing a PR and 9/12 had previously received an AI. Of the 43 patients with SD ≥6 months in duration, 26 had ER-positive and PgR-positive tumours. Among 18 patients with HER2-positive tumours, nine patients experienced SD, supporting the preclinical observation that fulvestrant can abrogate ER activation mediated by EGFR (Steger et al. 2005).

Data on the compassionate use of fulvestrant are also available from a more heavily pretreated cohort of 42 patients (50% had received ≥4 prior endocrine therapies and 38% had received ≥4 chemotherapy regimens) (Franco et al. 2004). All patients from this centre had received prior AI therapy. Despite the failure of various previous treatment options, eight patients (19%) experienced SD for ≥24 weeks; five had ER-positive and PgR-positive tumours and three had ER-positive and PgR-negative tumours. Three patients (two with ER-positive and PgR-negative tumours) had experienced SD for 14, 20 and 23+ months at the time data became available (Franco et al. 2004).

A further report has described an additional cohort of 64 pretreated patients (78% had received fulvestrant as second- or third-line endocrine therapy and 64% had received prior chemotherapy) (Petruzelka et al. 2004). In total, 39 patients (61%) experienced CB (CR + PR + SD ≥24 weeks), including five patients (8%) with an OR. A durable and ongoing OR was observed in 3/44 patients (≥18.5 to ≥21.2 months in duration), and 18/44 patients experienced ongoing SD of ≥24 weeks (≥6.5 to ≥20.3 months). Of the five patients with an OR, three had ER-positive and PgR-positive tumours and all had received prior non-steroidal AI treatment (Petruzelka et al. 2004).

These data provide further evidence for the lack of cross-resistance of fulvestrant with other endocrine

![Figure 5](https://www.endocrinology-journals.org)
agents, including the AIs, and confirm that fulvestrant can provide CB even in heavily pretreated postmenopausal women with advanced breast cancer. Moreover, there was evidence to suggest that the use of fulvestrant earlier in the treatment sequence led to better responses. In all of these compassionate-use analyses, fulvestrant was very well tolerated.

Tolerability of pure oestrogen antagonists

Owing to its pure oestrogen antagonistic effects, fulvestrant has the potential to offer an improved tolerability profile in the treatment of postmenopausal women with advanced breast cancer compared with other endocrine agents that have less targeted efficacy. The safety and tolerability findings of phase III studies of fulvestrant, both as first-line therapy and in patients with tamoxifen-resistant disease, are described below.

In the combined analysis of the two phase III trials of patients undergoing second-line treatment with fulvestrant and anastrozole, the safety population comprised 423 patients in each group (Robertson et al. 2003). Adverse events (AEs) were generally mild to moderate in intensity. The most commonly reported AEs with fulvestrant and anastrozole respectively were nausea (26.0 vs 25.3%), asthenia (22.7 vs 27.0%), pain (18.9 vs 20.3%), vasodilation (17.7 vs 17.3%) and headache (15.4 vs 16.8%). Seven predefined AEs were selected for statistical evaluation: gastrointestinal disturbances, hot flushes, joint disorders, thromboembolic disease, urinary tract infection, vaginitis and weight gain (Table 2). Of these, joint disorders was the only AE that was significantly different between the groups, experienced by fewer patients receiving fulvestrant (5.4 vs 10.6% with anastrozole; \( P = 0.0036 \)). Local injection-site reactions occurred in 1.1% of courses in patients given a single 5 ml injection, and in 4.6% and 4.4% of courses in patients given two 2.5 ml fulvestrant or placebo injections respectively. Only two patients (fulvestrant group) had injection-site reactions leading to withdrawal. Among patients receiving either fulvestrant or anastrozole, few patients withdrew due to AEs (2.8 vs 1.9% respectively) or drug-related AEs (0.9 vs 1.2% respectively). At long-term follow-up (median 27.0 months), no safety concerns had arisen in either treatment group (Howell et al. 2005).

In the study comparing fulvestrant and tamoxifen, the safety population comprised 310 and 271 patients, respectively, and the median follow-up was 14.5 months (Howell et al. 2004). The most commonly reported AEs in the fulvestrant and tamoxifen groups respectively, were nausea (20.3 vs 22.5%), asthenia (19.4 vs 20.3%), vasodilation (14.8 vs 21.4%), pain (13.9 vs 19.2%) and bone pain (13.9 vs 17.0%). Four predefined AEs (gastrointestinal disturbances, hot flushes, thromboembolic disease and vaginitis) were selected for statistical evaluation (Table 3). Of these, the incidence of hot flushes approached significance between the two groups, being lower among patients treated with fulvestrant (17.7 vs 24.7% with tamoxifen; \( P = 0.05 \)). There were also fewer gastrointestinal disturbances in the fulvestrant-treated patients (37.1 vs 43.2% in the tamoxifen group), but this difference was not significant (\( P = 0.16 \)). The incidence of thromboembolic events was higher in patients receiving fulvestrant in this study (5.8 vs 3.3%), but not significantly so (\( P = 0.22 \)). This apparent increase in thromboembolic events was not noted in the other phase III trials of fulvestrant (Howell et al. 2002, 2004, 2005).

### Table 2 Incidence of prospectively defined adverse events in patients receiving fulvestrant or anastrozole as second-line therapy.

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Fulvestrant (n = 423)</th>
<th>Anastrozole (n = 423)</th>
<th>( P )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal disturbances*</td>
<td>196 (46.3)</td>
<td>185 (43.7)</td>
<td>0.53</td>
</tr>
<tr>
<td>Hot flushes</td>
<td>89 (21.0)</td>
<td>87 (20.6)</td>
<td>0.91</td>
</tr>
<tr>
<td>Joint disorders†</td>
<td>23 (5.4)</td>
<td>45 (10.6)</td>
<td>0.036</td>
</tr>
<tr>
<td>Thromboembolic disease</td>
<td>15 (3.5)</td>
<td>17 (4.0)</td>
<td>0.68</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>31 (7.3)</td>
<td>18 (4.3)</td>
<td>0.06</td>
</tr>
<tr>
<td>Vaginitis</td>
<td>11 (2.6)</td>
<td>8 (1.9)</td>
<td>0.51</td>
</tr>
<tr>
<td>Weight gain</td>
<td>4 (0.9)</td>
<td>7 (1.7)</td>
<td>0.35</td>
</tr>
</tbody>
</table>

*Includes patients with nausea, vomiting, constipation and haemorrhage.
†Includes patients with arthralgia, arthrosis and arthritis.
Osborne et al. 2002) and no thromboembolic events were reported in two recent phase II studies (Ingle et al. 2004, 2006, Perey et al. 2004). Three patients receiving fulvestrant withdrew because of a drug-related AE (cerebrovascular accident, deep vein thrombosis and pulmonary embolus (one patient each)). No AEs leading to withdrawal were considered to be drug related in the tamoxifen group (Howell et al. 2004).

It is interesting to note that many so-called endocrine treatment-related AEs have also been noted in patients receiving placebo in breast cancer trials. For example, in the NCIC CTG MA.17 trial, postmenopausal patients receiving letrozole following 5 years of tamoxifen treatment experienced a similar frequency of oedema (17.2 vs 15.6%), fatigue (29.9 vs 28.3%), sweating (22.1 vs 20.7%), and headache (18.1 vs 18.6%) as placebo-treated patients (Goss et al. 2003). Therefore, it is difficult to determine which AEs are truly fulvestrant-related without the use of placebo-controlled studies.

The effects of fulvestrant on bone mineral density and markers of bone turnover are not fully elucidated, and have not yet been reported in postmenopausal women. Preclinical studies in rats suggest that fulvestrant reduces cancellous bone volume, which comprises only a small proportion of total bone (Gallagher et al. 1993, Sibonga et al. 1998) and its effects are consistent with blockade of ER-mediated bone resorption and formation (Wakeling 1995). Despite the lack of uterotrophic activity with fulvestrant, some agonistic effects on bone were apparent in the second study, which were highly dependent on circulating oestrogen levels (Sibonga et al. 1998). In a study involving 307 premenopausal women with uterine fibroids awaiting hysterectomy, fulvestrant did not produce changes in markers of bone resorption (cross-linked N-telopeptides and free deoxypyridinoline), suggesting it did not affect bone turnover in this patient group (Donnez et al. 2003). However, the high circulating oestrogen levels in premenopausal women may have negated any impact of fulvestrant on bone turnover in this study. Further studies are required to assess any impact on bone in postmenopausal women.

Future directions

The sequential use of endocrine agents is a standard treatment strategy for advanced breast cancer. However, as non-steroidal AIs are now replacing tamoxifen as the first-line choice, the optimal sequence of endocrine therapy needs to be re-evaluated in order to maximise the benefit that patients will gain from these treatments. While direct comparisons between endocrine therapies are not always available, indirect comparisons suggest that fulvestrant offers comparable efficacy and may also have tolerability advantages over some AIs in the second-line treatment of postmenopausal women with advanced breast cancer (Dodwell & Vergote 2005). In the treatment of advanced breast cancer, third-generation AIs (e.g. anastrozole, letrozole and exemestane) have superior efficacy to tamoxifen and have become the first-line therapy of choice in this disease setting (Nabholtz et al. 2000, Mouridsen et al. 2003, Paridaens et al. 2003). Clearly, the most effective endocrine therapy should always be used first and, in cases where therapies are equally effective, the best-tolerated agent should be used first. A second key consideration is that cross-resistance is less likely to occur if endocrine therapies with different modes of action are used. Finally, tumour sensitivity to subsequent endocrine therapies should be maintained.

Two large phase III trials have provided evidence that tamoxifen-resistant tumours remain sensitive to fulvestrant (Howell et al. 2002, Osborne et al. 2002). Furthermore, a phase II trial has shown that of 67 patients who developed resistance initially to tamoxifen...
and then to an AI, 28.4% subsequently gained CB (CR + PR + SD ≥ 24 weeks) with fulvestrant (median treatment duration 3.8 months) (Perey et al. 2004). Similarly, in another phase II trial of 77 patients with advanced breast cancer who had progressed on prior AI therapy (21 had also received tamoxifen), 32.5% gained CB with fulvestrant (Ingle et al. 2004, 2006). Additionally, in the compassionate-use programme, CB was achieved in patients who received fulvestrant after progression on prior endocrine therapies, including both AIs and SERMs (Petruzelka et al. 2004, Steger et al. 2005). Importantly, tumour sensitivity to subsequent endocrine therapies appears to be maintained after fulvestrant treatment (Vergote et al. 2003, Robertson et al. 2005).

Taken together, these data position fulvestrant as a versatile agent that may be used in the second-line setting after tamoxifen, or potentially after AIs. However, initiating fulvestrant earlier in the treatment sequence may lead to better and more durable responses. Fulvestrant is now approved for the treatment of postmenopausal women with ER-positive, locally advanced or metastatic breast cancer who have either relapsed on prior adjuvant oestrogen antagonist therapy or progressed on prior oestrogen antagonist therapies. After progression on fulvestrant, endocrine therapies such as megestrol acetate or the steroidal AI exemestane may be the next appropriate drug.

Several new trials of fulvestrant are now under way to further validate its optimum position in the endocrine treatment sequence for advanced breast cancer. The Evaluation of Faslodex and Exemestane Clinical Trial (EFECT) includes postmenopausal patients with ER-positive and/or PgR-positive breast tumours who have experienced recurrence or progression on a non-steroidal AI. Patients will be randomised for double-dummy treatment with fulvestrant (loading dose: 500 mg i.m. on day 1 and 250 mg on day 14, plus a 250 mg on day 28 and every month thereafter) or exemestane (25 mg/day orally). The primary endpoint of this study is TTP. In a second post-AI trial (Study Of Faslodex vs Exemestane with/without Arimidex (SOFEA)), postmenopausal patients with locally advanced or metastatic breast cancer (ER positive) who have recurred/progressed on treatment with non-steroidal AIs will be randomised to treatment with fulvestrant, fulvestrant plus anastrozole, or exemestane. In this study, as well as in EFECT and Faslodex and Arimidex Clinical Trial (FACT), the time to steady state of fulvestrant will be examined more closely in order to optimise loading-dose regimens. Ongoing and planned studies will also examine combination therapies, including those in which fulvestrant is co-administered with anastrozole (vs anastrozole alone in SOFEA and FACT) and the novel anti-epidermal growth factor receptor EGFR/HER2 agents gefitinib (ECOG 4101) and trastuzumab.

Other pure oestrogen antagonists in development

Although fulvestrant is the first pure oestrogen antagonist, several other pure oestrogen antagonists are undergoing preclinical development. Two new pure oestrogen antagonists, ZK-703 and ZK-253, which destabilise the ER, have been investigated using the MCF-7 xenograft model. ZK-703 and ZK-253 were not only more effective than either tamoxifen or fulvestrant at inhibiting the growth of ER-positive xenografts, they also showed a highly potent activity in tamoxifen-resistant xenografts (Hoffmann et al. 2004). Clinical studies with both of these agents are awaited with interest. Ospemifene (FC-1271a), a SERM being developed for the treatment of osteoporosis, has been observed to inhibit MCF-7 tumour growth in vivo when compared with control (P ≤ 0.05; Taras et al. 2001), and further studies are required to evaluate its efficacy in the clinical setting. Another steroidal oestrogen antagonist that has undergone preclinical investigation with promising results is RU 58668, which has been shown to induce long-term regression of MCF-7 xenografts (van de Velde et al. 1994). These data suggest that RU 58668 may have potential for the treatment of advanced breast cancer. To date, however, there do not appear to be any clinical trials that are evaluating RU 58668 in the breast cancer setting.

Two non-steroidal fourth-generation SERMs that exert complete oestrogen antagonistic effects on the breast and uterus have been developed–aclol bifene (EM-652) and its highly potent precursor EM-800 (Gauthier et al. 1997, Labrie et al. 1999). In a preclinical xenograft (ZR-75-1) study, EM-652 caused the complete disappearance of 65% of tumours and no tumours progressed (Roy et al. 2003). Moreover, 93% of tumours that had disappeared using EM-652 did not reappear when exposed to oestrogen challenge for 12 weeks (Roy et al. 2003). Development of EM-652 is ongoing. The development of EM-800 for advanced breast cancer has been halted, despite 35% of patients (n = 43) with tamoxifen-resistant breast cancer who had been treated with EM-800 experiencing CB in a phase II study (Labrie et al. 2004). In comparison, >43.5% of tamoxifen-resistant patients treated with fulvestrant experience CB (Robertson et al. 2003).
TAS-108 is a synthetic ER ligand that blocks ER-α transactivation but has an agonistic effect on ER-β (Yamamoto et al. 2005). In a phase I study in 16 patients who had received 6 to 7 prior therapies, pharmacokinetic findings were favourable and there was evidence of biological anti-tumour activity (Blakely et al. 2004). Phase II studies involving TAS-108 are planned in the USA.

Conclusions
There is a clear need for the development of oestrogen antagonistic drugs that match the clinical efficacy of tamoxifen but lack any partial agonist effects. Fulvestrant is the first ‘pure’ oestrogen antagonist to be extensively characterised and to enter clinical use. In postmenopausal women with advanced breast cancer, fulvestrant represents a valuable and versatile new option for endocrine therapy.

Acknowledgements
The author would like to thank Carolyn Gray, PhD, for her editorial assistance with this manuscript.

Funding
The author declares that he has no conflicts of interest that would prejudice the impartiality of this article.

References


Berry M, Metzger D & Chambon P 1990 Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO Journal 9 2811–2818.


A Howell: Pure anti-oestrogens in advanced breast cancer


transcription, supporting a “Ying Yang” relationship between ERα and ERβ in mice. *Molecular Endocrinology* **17** 203–208.


Perey L, Pariarda R, Nolé F, Bonnefoi H, Aebi S, Goldhirsch A, Dietrich D & Thürlimann B for the Swiss...


Vergote I, Robertson JFR, Kleeberg U, Burton G, Osborne CK & Mauriac L 2003 Postmenopausal women who...
progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. *Breast Cancer Research and Treatment* **79** 207–211.


